摘要
目的研究分析帕金森病患者接受盐酸苯海索联合吡贝地尔治疗的临床效果和安全性,为临床用药治疗提供参考。方法根据2012年9月—2016年3月我院的92例帕金森病患者来分析研究,将患者分成对照组和研究组,均有46例,对照组使用吡贝地尔治疗,研究组使用吡贝地尔和盐酸苯海索联合治疗,对两组治疗前后的帕金森综合评定量表(UPDRS)评分和Webster评分进行对比分析。结果治疗前两组的UPDRS评分、Webster评分差异无统计学意义(P>0.05),治疗后两组UPDRS、Webster评分均有所下降,研究组的降低幅度比对照组大,差异有统计学意义(P<0.05)。结论帕金森病患者临床中选择盐酸苯海索联合吡贝地尔治疗的效果比较突出,患者的症状改善明显,生活质量显著提升,不良反应率比较低,安全可靠。
Objective To study The clinical effect and safety of Benzhexol hydrochloride combined with piribedil in treatment of Parkinson＇s disease. Methods 92 patients with Parkinson were analyzed in our hospital from September 2012 to March 2016. The patients were divided into the control group and the study group, with 46 cases in each. The control group used piribedil for treatment, study group used piribedil and trihexyphenidyl hydrochloride for combined treatment. The Parkinson comprehensive rating scale （UPDRS） score and Webster score before and after treatment were compared and analyzed between the two groups. Results There was no significant difference in UPDRS score and Webster score between the two groups before treatment （P 〉 0.05）. After treatment, the scores of UPDRS and Webster decreased in the two groups, and the decrease rate in the study group was larger than that in the control group, and the difference was statistically significant （P 〈 0.05）. Conclusion Parkinson with Benzhexol hydrochloride combined with piribedil for treatment is prominent. The symptoms of the patients improved significantly, the quality of life improved significantly, the rate of adverse reactions was low, safe and reliable.
出处
《中国卫生标准管理》
2017年第18期84-85,共2页
China Health Standard Management
关键词
盐酸苯海索
吡贝地尔
帕金森病
临床症状
benzhexol hydrochloride
piribedil
Parkinson＇s disease
clinical symptoms
